The Federal Budget announced last night has introduced several major reforms to the Australian R&D Tax Incentive (RDTI) program, creating significant new opportunities for emerging biotech companies developing novel therapeutics, advancing clinical programs, and scaling manufacturing activities in Australia.
For biotech companies, navigating rising global development costs and increasingly constrained funding environments, these reforms reinforce Australia as one of the most attractive locations globally for early-stage drug development and clinical trials.
At PharmSky, we believe these changes create an even stronger case for biotech companies to partner with an Australian CDMO, capable of providing an integrated CMC service from API sourcing all the way to clinical trial manufacturing and distribution.
As an Australian Registered Service Provider (RSP), PharmSky enables eligible clients to potentially claim a broad range of development activities undertaken with our team under the Australian R&D Tax Incentive program, helping companies maximise their budgets while accelerating development timelines.
Increased R&D Threshold Creates New Opportunities for Scaling Biotechs
One of the most impactful reforms announced in the Federal Budget is the increase to the refundable R&D tax offset turnover threshold from $20 million to $50 million aggregated turnover.
This is a major win for scaling biotech companies progressing through later clinical development phases. Previously, many growing companies risked losing access to refundable R&D incentives as their turnover increased, often forcing difficult decisions around where future development activities would be conducted.
Under the updated framework, eligible biotech companies under 10 years old can continue accessing refundable R&D support so long as their aggregate turnover is under $50 million, that’s a 150% increase to the cap from previous years.
The increase in the turnover threshold also creates meaningful advantages for later-stage biotech companies and sponsors.
Historically, companies often transitioned development activities offshore once they exceeded earlier turnover limits. The new structure now supports companies remaining in Australia longer as they scale, reducing the need for disruptive tech transfers and fragmented global supply chains.
At PharmSky, we help companies maintain continuity across the development lifecycle through an integrated CMC and clinical supply service, designed specifically for emerging biotech programs.
Our team supports clients through:
- Early formulation and feasibility studies
- Drug product and process development
- Analytical method development and validation
- GMP clinical manufacturing
- Stability studies
- Clinical trial material supply
- Regulatory support and technical documentation
By consolidating these capabilities within a single CDMO partner like PharmSky, our clients can streamline communication, reduce operational complexity, and accelerate progression into clinical trials.
PharmSky’s RSP Status Provides Additional Value for Emerging Biotechs
As a Registered Service Provider (RSP) with the Australian Federal Government, PharmSky is uniquely positioned to support early-stage biotech companies, startups, and international sponsors seeking to establish development activities in Australia while maximising eligibility under the R&D Tax Incentive program.
This is particularly valuable for companies undertaking:
- Early proof-of-concept studies
- Small-scale formulation programs
- Analytical testing
- Clinical trial manufacturing
- Pilot GMP batches
- Clinical supply
For many early-stage companies, R&D incentives can materially extend runway, improve capital efficiency, and allow programs to advance further before requiring additional fundraising.
An End-to-End Development Partner for Clinical Translation
At PharmSky, our focus is helping biotech companies move faster from concept to clinic through an integrated, science-driven development strategy.
We understand the challenges faced by emerging biotech companies:
- Limited internal CMC infrastructure
- Pressure to reduce timelines
- Capital constraints
- Increasing regulatory complexity
- The need for flexible manufacturing and supply solutions
Our services are designed specifically to address these challenges by providing agile, end-to-end support all under one roof.
Whether supporting a first-in-human program, scaling a formulation process, manufacturing GMP clinical trial material, or managing clinical supply logistics, PharmSky works as an extension of our clients development teams to help de-risk programs and accelerate clinical translation.
Australia’s Innovation Ecosystem Is Becoming Even More Attractive
Combined with Australia’s globally respected clinical trial environment, efficient regulatory pathways, strong IP protections, and highly skilled scientific workforce, the 2026/2027 Federal Budget reforms further strengthen Australia’s position as a leading destination for biotech innovation.
For emerging biotech companies looking to maximise R&D incentives while accessing high-quality scientific and manufacturing capabilities, partnering with an Australian RSP like PharmSky provides both strategic and financial advantages.
As these reforms take effect, PharmSky is excited to continue supporting Australian and international biotech innovators with integrated CMC, manufacturing, and clinical supply solutions designed to help bring new therapies to patients faster.
To learn more about how PharmSky can support your development program and help maximise available R&D incentives in Australia, contact our team today at info@pharmsky.com.
